Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Daniel C. Freed"'
Autor:
Leike Li, Daniel C. Freed, Yaping Liu, Fengsheng Li, Diane F. Barrett, Wei Xiong, Xiaohua Ye, Stuart P. Adler, Richard E. Rupp, Dai Wang, Ningyan Zhang, Tong-Ming Fu, Zhiqiang An
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, V160, was shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-controlled phase I clinical trial (NCT01986010). However, the specificiti
Externí odkaz:
https://doaj.org/article/8407aee0085d434d8f8d2b457a78ae7d
Autor:
Ying Qi, Li He, Xiaohong Cui, Laura Hertel, Daniel C. Freed, Tong-Ming Fu, Lawrence M. Kauvar, Michael A. McVoy, Qiang Ruan
Publikováno v:
Virology Journal, Vol 17, Iss 1, Pp 1-7 (2020)
Abstract Antibody neutralization of cytomegalovirus (CMV) entry into diverse cell types is a key consideration for development of vaccines and immunotherapeutics. CMV entry into fibroblasts differs significantly from entry into epithelial or endothel
Externí odkaz:
https://doaj.org/article/8f1024c2a3ed43b395ff4e6e9054c92e
Autor:
Gokul Swaminathan, Michael Citron, Jianying Xiao, James E. Norton, Abigail L. Reens, Begüm D. Topçuoğlu, Julia M. Maritz, Keun-Joong Lee, Daniel C. Freed, Teresa M. Weber, Cory H. White, Mahika Kadam, Erin Spofford, Erin Bryant-Hall, Gino Salituro, Sushma Kommineni, Xue Liang, Olga Danilchanka, Jane A. Fontenot, Christopher H. Woelk, Dario A. Gutierrez, Daria J. Hazuda, Geoffrey D. Hannigan
Publikováno v:
Vaccines, Vol 9, Iss 11, p 1340 (2021)
Emerging evidence demonstrates a connection between microbiome composition and suboptimal response to vaccines (vaccine hyporesponse). Harnessing the interaction between microbes and the immune system could provide novel therapeutic strategies for im
Externí odkaz:
https://doaj.org/article/c57141bfb4b545c0b73222a00565d3e1
Autor:
Aimin Tang, Daniel C. Freed, Fengsheng Li, Steve Meschino, Michael Prokop, Andrew Bett, Danilo Casimiro, Dai Wang, Tong-Ming Fu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 12, Pp 2763-2771 (2017)
T cell immunity is critical in controlling human cytomegalovirus (HCMV) infection in transplant recipients, and T cells targeting viral immediate early proteins such as IE1, IE2 and pp65 have been speculated to be more effective against reactivation.
Externí odkaz:
https://doaj.org/article/dd698df3143a40e3828f2012477d580b
Autor:
Takako Tabata, Matthew Petitt, June Fang-Hoover, Daniel C. Freed, Fengsheng Li, Zhiqiang An, Dai Wang, Tong-Ming Fu, Lenore Pereira
Publikováno v:
Vaccines, Vol 7, Iss 4, p 135 (2019)
Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown. We measured the efficacy of human monoclonal antibodies
Externí odkaz:
https://doaj.org/article/cfbefa7f6f164a1590288f210bc35b7a
Autor:
Daniel Wrapp, Xiaohua Ye, Zhiqiang Ku, Hang Su, Harrison G. Jones, Nianshuang Wang, Akaash K. Mishra, Daniel C. Freed, Fengsheng Li, Aimin Tang, Leike Li, Dabbu Kumar Jaijyan, Hua Zhu, Dai Wang, Tong-Ming Fu, Ningyan Zhang, Zhiqiang An, Jason S. McLellan
Publikováno v:
Science Advances. 8
Human cytomegalovirus (HCMV) encodes multiple surface glycoprotein complexes to infect a variety of cell types. The HCMV Pentamer, composed of gH, gL, UL128, UL130, and UL131A, enhances entry into epithelial, endothelial, and myeloid cells by interac
Autor:
Kalpit A. Vora, Lu Zhang, I-Ming Wang, Shifang Zhang, Aimin Tang, Richard E. Rupp, Kara S. Cox, Dai Wang, Daniel C. Freed, Stuart P. Adler, Luwy Musey, Yu Zhou, Tong-Ming Fu
Publikováno v:
The Journal of Infectious Diseases. 223:2001-2012
Background Cytomegalovirus (CMV) can cause congenital infection and is the leading cause of nongenetic newborn disabilities. V160, a conditionally replication-defective virus, is an investigational vaccine under evaluation for prevention of congenita
Autor:
Jennifer A. Jenks, Joshua J. Tu, Ningyan Zhang, Jesse F. Mangold, Dai Wang, Helen S. Webster, Tong-Ming Fu, Sallie R. Permar, Matthew L. Goodwin, Whitney Edwards, Jason S. McLellan, Justin Pollara, Hsuan-Yuan Wang, Daniel Wrapp, Cody S. Nelson, Sarah M. Valencia, Daniel C. Freed, Zhiqiang An
Publikováno v:
Virology
Human cytomegalovirus (HCMV) is the most common congenital infection. A glycoprotein B (gB) subunit vaccine (gB/MF59) is the most efficacious clinically tested to date, having achieved 50% protection against primary infection of HCMV-seronegative wom
Autor:
Xue Liang, Begüm D. Topçuoğlu, Erin Spofford, Julia M. Maritz, Sushma Kommineni, Cory H. White, Olga Danilchanka, Daria J. Hazuda, Geoffrey D. Hannigan, Teresa M. Weber, Michael P. Citron, Jianying Xiao, Christopher H. Woelk, Daniel C. Freed, Erin Bryant-Hall, Keun-Joong Lee, Jane Fontenot, Gokul Swaminathan, Gino Salituro, Dario A. Gutierrez, Mahika Kadam, James E. Norton, Abigail L. Reens
Publikováno v:
Vaccines
Volume 9
Issue 11
Vaccines, Vol 9, Iss 1340, p 1340 (2021)
Volume 9
Issue 11
Vaccines, Vol 9, Iss 1340, p 1340 (2021)
Emerging evidence demonstrates a connection between microbiome composition and suboptimal response to vaccines (vaccine hyporesponse). Harnessing the interaction between microbes and the immune system could provide novel therapeutic strategies for im
Autor:
Fengsheng Li, Morgan A. Monslow, Amy S. Espeseth, Kalpit A. Vora, Dai Wang, Dan Chang, Tong-Ming Fu, Marian E. Gindy, Daniel C. Freed, Nikolai Petrovsky, Hualin Li
Publikováno v:
Vaccine. 39(51)
Adjuvants have long been explored to enhance vaccine efficacy. Current adjuvants approved for human vaccines are mostly studied for their ability to improve antibody responses. There remains a need for development of novel adjuvants, especially those